Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael D. Tarantino, MD, Nichola Cooper, Donald Beam, Jenny M. Despotovic, DO, Alexey A. Maschan, MD, Kejia Wang, PhD, Melissa Jeanne Eisen, MD, Charles Bowers, MD

Blood (2019) 134 (Supplement_1): 1095.

https://doi.org/10.1182/blood-2019-131241

Published: 2019

Journal Articles

Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials

Michael D. Tarantino, MD, Jenny M. Despotovic, DO, MS, John Roy, John Grainger, MD MRCP, FRPATH, Nichola Cooper, MRCP, Donald Beam, Ashok Raj, Alexey A. Maschan, MD, June Kim, PhD, Melissa Jeanne Eisen, MD

Blood (2018) 132 (Supplement 1): 2428.

https://doi.org/10.1182/blood-2018-99-109763

Published: 2018

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John D. Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael Tarantino, Nicola Cooper, MA, MD MRCP, FRCPath, Donald Beam, Jenny M. Despotovic, DO, MS, Alexey Maschan, MD PhD Professor, Nancy Carpenter, Melissa Eisen, Joseph Park

Blood (2017) 130 (Supplement 1): 2334.

https://doi.org/10.1182/blood.V130.Suppl_1.2334.2334

Published: 2017

Journal Articles

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael Tarantino, James B. Bussel, MD, Victor S. Blanchette, MD, Donald Beam, John Roy, Jenny M. Despotovic, DO, MS, Ashok Raj, Nancy Carpenter, Bhakti Mehta, Melissa Eisen

Blood (2017) 130 (Supplement 1): 14.

https://doi.org/10.1182/blood.V130.Suppl_1.14.14

Published: 2017

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Michael D. Tarantino, Victor S. Blanchette, Ashok Raj, Jenny Despotovic, Donald Beam, John Roy, Xuena Wang, Bhakti Mehta, Melissa Eisen

Blood (2016) 128 (22): 3738.

https://doi.org/10.1182/blood.V128.22.3738.3738

Published: 2016

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, MD, Victor S. Blanchette, MD FRCP, Jenny M. Despotovic, DO, MS, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, DO, Kun Nie, Melissa Eisen, MD

Blood (2015) 126 (23): 3467.

https://doi.org/10.1182/blood.V126.23.3467.3467

Published: 2015

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, Victor S. Blanchette, Jenny Despotovic, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Nancy Carpenter, Kun Nie, Melissa Eisen

Blood (2015) 126 (23): 7.

https://doi.org/10.1182/blood.V126.23.7.7

Published: 2015

NARROW

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Email alerts

ASH Publications

American Society of Hematology

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only